{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:17:32Z","timestamp":1778249852402,"version":"3.51.4"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["grant no. ZR2022QH127"],"award-info":[{"award-number":["grant no. ZR2022QH127"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Radioiodine (RAI) therapy, while established for Graves\u2019 hyperthyroidism (GH), exhibits variable efficacy (50-80% cure rates), with non-complete remission (NCR) necessitating retreatment. In the study, we aimed to identify independent predictors of NCR and develop a validated nomogram for personalized RAI outcome prediction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from 285 GH patients undergoing initial RAI therapy were retrospectively analyzed and randomly allocated into training (n=199) and validation (n=86) cohorts at a 7:3 ratio. Univariate followed by multivariate logistic regression identified independent predictors of NCR in the training cohort. These variables informed the construction of a prognostic nomogram model, subsequently verified in the validation cohort through calibration, receiver operating characteristic (ROC) curve, and decision curve analysis (DCA) to assess model reliability, discriminative ability, and clinical utility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thyroid mass (TM), 24-hour RAI uptake (RAIU24h), effective half-life (Teff), and free triiodothyronine reduction at 1-month post-therapy (\u0394FT3) were independent predictors. The prognostic nomogram integrating these variables exhibited superior discriminative performance in both training (AUC = 0.919) and validation cohorts (AUC = 0.901). Calibration curves confirmed high fidelity between predicted and observed NCR probabilities. DCA demonstrated significant clinical net benefit across threshold probabilities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TM, RAIU24h, Teff, and \u0394FT3 are critical determinants of RAI efficacy in GH. The validated nomogram enables precise NCR risk stratification, facilitating optimized activity prescription to improve remission rates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1692702","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:18:05Z","timestamp":1761628685000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A prognostic nomogram model for non-complete remission following initial radioiodine therapy in Graves\u2019 hyperthyroidism"],"prefix":"10.3389","volume":"16","author":[{"given":"Congcong","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohua","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhui","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xufu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1186\/s13044-022-00126-4","article-title":"Radioiodine treatment outcome by dosimetric parameters and renal function in hyperthyroidism","volume":"15","author":"Nilsson","year":"2022","journal-title":"Thyroid Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2018.18","article-title":"Global epidemiology of hyperthyroidism and hypothyroidism","volume":"14","author":"Taylor","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00005-0","article-title":"Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis","volume":"11","author":"Wiersinga","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1159\/000490384","article-title":"2018 european thyroid association guideline for the management of graves\u2019 Hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur Thyroid J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0229","article-title":"2016 american thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"B6","doi-asserted-by":"publisher","first-page":"456","DOI":"10.4158\/ep.17.3.456","article-title":"Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists","volume":"17","author":"Bahn","year":"2011","journal-title":"Endocr Pract"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2802","article-title":"A 2011 survey of clinical practice patterns in the management of Graves\u2019 disease","volume":"97","author":"Burch","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e928796","DOI":"10.12659\/MSM.928796","article-title":"Predictive value of a thyroid-absorbed dose with a shorter effective half-life on efficacy in graves disease patients receiving iodine-131 therapy","volume":"27","author":"Yu","year":"2021","journal-title":"Med Sci Monit"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1391014","article-title":"Nomogram construction and evaluation for predicting non-remission after a single radioactive iodine therapy for Graves\u2019 hyperthyroidism: a retrospective cohort study","volume":"15","author":"Yu","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ecl.2021.12.004","article-title":"2022 update on clinical management of graves disease and thyroid eye disease","volume":"51","author":"Hoang","year":"2022","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1628226","article-title":"Development and validation of a nomogram prediction model for factors influencing 131I-refractory Graves\u2019 hyperthyroidism","volume":"16","author":"Liao","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000002045","article-title":"Predictive factors for the efficacy of radioiodine therapy in patients with Graves\u2019 disease","author":"Iwanaga","year":"2025","journal-title":"Nucl Med Commun"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn321828-20201109-00405","article-title":"Clinical guidelines for 131I treatment of Graves\u2019 hyperthyroidism (2021 edition)","volume":"41","year":"2021","journal-title":"Chin J Nucl Med Mol Imaging"},{"key":"B14","doi-asserted-by":"publisher","first-page":"095015","DOI":"10.1088\/1361-6560\/ab186d","article-title":"Estimation of thyroid volume from scintigraphy through 2D\/3D registration of a statistical shape model","volume":"64","author":"Wang","year":"2019","journal-title":"Phys Med Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020805","article-title":"A randomized comparison of radioiodine doses in graves\u2019 Hyperthyroidism","volume":"88","author":"Leslie","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0000000000000288","article-title":"Predictive factors of outcomes in personalized radioactive iodine ((131)I) treatment for Graves\u2019 disease","volume":"348","author":"Liu","year":"2014","journal-title":"Am J Med Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/er.2012-1030","article-title":"Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome","volume":"33","author":"Bonnema","year":"2012","journal-title":"Endocr Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/MNM.0b013e32834d3bb9","article-title":"Analysis of 131I therapy and correlation factors of Graves\u2019 disease patients: a 4-year retrospective study","volume":"33","author":"Zheng","year":"2012","journal-title":"Nucl Med Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1999.9.1181","article-title":"Radioiodine therapy in Graves\u2019 disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy","volume":"9","author":"Sabri","year":"1999","journal-title":"Thyroid"},{"key":"B20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/MNM.0000000000000770","article-title":"Prognostic factor analysis in 325 patients with Graves\u2019 disease treated with radioiodine therapy","volume":"39","author":"Yang","year":"2018","journal-title":"Nucl Med Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20191609","article-title":"Predictive factors for the outcomes of Graves\u2019 disease patients with radioactive iodine (131I) treatment","volume":"40","author":"Xing","year":"2020","journal-title":"Biosci Rep"},{"key":"B22","article-title":"Optimal iodine-131 dose for eliminating hyperthyroidism in Graves\u2019 disease","volume":"32","author":"Nordyke","year":"1991","journal-title":"J Nucl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-097X.2006.00666.x","article-title":"Radioiodine therapy in hyperthyroid disease: poorer outcome in patients with high 24 hours radioiodine uptake","volume":"26","author":"Kristoffersen","year":"2006","journal-title":"Clin Physiol Funct Imaging"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e3182817c78","article-title":"High failure rates after (131)I therapy in Graves hyperthyroidism patients with large thyroid volumes, high iodine uptake, and high iodine turnover","volume":"38","author":"de Jong","year":"2013","journal-title":"Clin Nucl Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/47\/9\/305","article-title":"A theoretical model for prescription of the patient-specific therapeutic activity for radioiodine therapy of Graves\u2019 disease","volume":"47","author":"Di Martino","year":"2002","journal-title":"Phys Med Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s002590000348","article-title":"Does thyroid stunning exist? A model with benign thyroid disease","volume":"27","author":"Sabri","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-01833-5","article-title":"Thyroid stunning in radioiodine-131 therapy of benign thyroid diseases","volume":"63","author":"Happel","year":"2019","journal-title":"Endocrine"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e31824851d1","article-title":"Predictive factors of failure in a fixed 15 mCi 131I-iodide therapy for Graves\u2019 disease","volume":"37","author":"Moura-Neto","year":"2012","journal-title":"Clin Nucl Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.5603\/EP.2015.0019","article-title":"Radioiodine therapy for Graves\u2019 disease - retrospective analysis of efficacy factors","volume":"66","author":"Szumowski","year":"2015","journal-title":"Endokrynol Pol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3210317","article-title":"A case of thyrotoxicosis due to simultaneous occurrence of subacute thyroiditis and graves\u2019 Disease","volume":"2018","author":"Kageyama","year":"2018","journal-title":"Case Rep Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1210\/endo-105-2-548","article-title":"Changes in the particulate subcellular component of hepatic thyroxine-5\u2019-monodeiodinase in hyperthyroid and hypothyroid rats","volume":"105","author":"Kaplan","year":"1979","journal-title":"Endocrinology"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1692702\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:18:07Z","timestamp":1761628687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1692702\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":31,"alternative-id":["10.3389\/fendo.2025.1692702"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1692702","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"article-number":"1692702"}}